SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Innovative Growth Strategies by Safe & Green Holdings Corp.
- Enhancing Urban Green Spaces: The Evolution of Barrios Unidos Park
- PMGC Capital's Strategic Investment in Alaunos Therapeutics
- Entrée Resources Reveals Promising Drill Results from HNE
- Viasat and Blue Origin Collaboration Simplifies Launch Telemetry
- aTyr Pharma's ATYR0101: A New Dawn in Pulmonary Fibrosis Care
- Sow Good Inc. Shows Effective Growth in Q1 2025 Results
- Explore New Homes for Sale at Henson Creek Farms
- SailPoint's Upcoming Fiscal Q1 2026 Insights and Expectations
- Exploring BETR-001: A New Era in Treating Mental Health
- Redfin Partners with Magnite to Enhance Audience Targeting
- Indaptus Therapeutics Unveils 2025 Q1 Results and Updates
- Heartland Oncology's Dr. Hussain Celebrated as Advocacy Leader
- Kalaris Therapeutics Reports Strong Q1 2025 Financial Growth
- Aprea Therapeutics' Clinical Progress and Financial Update
- Enphase Energy Expands Incentives for Home Battery Installations
- Pacira BioSciences Announces Participation in Key Healthcare Events
- Landsbankinn hf. Successes in Covered Bond Exchange Offer
- IO Biotech's Recent Advances in Cancer Vaccine Development
- Insightful Trends: American Brands Flourish Amid Consumer Shifts
- Qvinci Software Launches Cutting-Edge Financial Tools for Growth
- Bench International Unveils Flexible Leadership Solutions
- Aethlon Medical's Hemopurifier: A New Era in Oncology Treatments
- symplr Achieves Prestigious Best Managed Company Recognition
- Lucid Diagnostics Reveals Q1 2025 Financial Performance Insights
- Exciting Growth of WareSpace in Texas Market Expansion
- Discover the Cutting-Edge Samsung Galaxy S25 Edge with Boost
- Revolutionizing Maritime Security with Seasats' Lightfish System
- Enhancing Global Sanctions Training with Industry Leaders' Alliance
- Global Partnerships Enhance Sanctions Training Program Expansion
- Presage Global Triumphs at Family Wealth Report Awards 2025
- Vintage Investment Partners Expands into Europe with New Office
- Stark Future Reaches New Heights in Electric Motorcycle Sales
- Strolid Names Michael Donovan as VP of Marketing for Growth
- PSI Services to Enhance Insurance Licensing in New Partnership
- Moleculin Biotech's Q1 2025 Update: Progress and Results Ahead
- ADC Therapeutics Showcases LOTIS-7 Clinical Data at Global Conference
- Pharmaceutical Container Market Forecast: Exponential Growth Ahead
- Jacobs Inks Deal as Integrated Partner for Energy Project
- Unlocking Decentralization with UXUY Protocol's Innovations
- Job Seekers Reveal Economic Woes and Workplace Dissatisfaction
- Waterfall Network Launches Groundbreaking Tools for Web3 Innovation
- INE Security Enhances Cyber Defense Training with New Labs
- Pioneering Gene Therapy at Lurie Children's for Skin Disorders
- A Partnership for Growth: Glass House Brands and LEEF Team Up
- Strategic Partnership Between Glass House Brands and LEEF
- Avis Budget Group Announces Major $500 Million Notes Offering
- nCino Schedules Conference Call for First Quarter Results
- BioVie Announces Virtual Event for Parkinson's Treatment Discussion
- Stallion Uranium Faces Cease Trade Order and Future Plans